(2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2)

Discovery of a biased mu/delta opioid receptor agonist

Lorella Pasquinucci, Rita Turnaturi, Girolamo Calò, Francesco Pappalardo, Federica Ferrari, Giulia Russo, Emanuela Arena, Lucia Montenegro, Santina Chiechio, Orazio Prezzavento, Carmela Parenti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The pivotal role of the stereocenter at the N-substituent of the 6,7-benzomorphan scaffold was investigated combining synthetic and pharmacological approaches. 2R- and 2S-diastereoisomers of the multitarget MOR/DOR antinociceptive ligand LP2 (1) were synthesized and their pharmacological profile was evaluated in in vitro and vivo assays. From our results, 2S-LP2 (5) showed an improved pharmacological profile in comparison to LP2 (1) and 2R-LP2 (4). 2S-LP2 (5) elicited an antinociceptive effect with a 1.5- and 3-times higher potency than LP2 (1) and R-antipode (4), respectively. In vivo effect of 2S-LP2 (5) was consistent with the improved MOR/DOR efficacy profile assessed by radioligand binding assay, to evaluate the opioid receptor affinity, and BRET assay, to evaluate the capability to promote receptor/G-protein and receptor/β-arrestin 2 interaction. 2S-LP2 (5) was able to activate, with different efficacy, G-protein pathway over β-arrestin 2, behaving as biased agonist at MOR and mainly at DOR. Considering the therapeutic potential of both multitarget MOR/DOR agonism and functional selectivity over G-protein, the 2S-LP2 (5) biased multitarget MOR/DOR agonist could provide a safer treatment opportunity.

Original languageEnglish
Pages (from-to)189-198
Number of pages10
JournalEuropean Journal of Medicinal Chemistry
Volume168
DOIs
Publication statusPublished - Apr 15 2019

Fingerprint

Benzomorphans
delta Opioid Receptor
mu Opioid Receptor
GTP-Binding Proteins
Arrestin
Assays
Pharmacology
Radioligand Assay
Opioid Receptors
Scaffolds
Ligands
beta-Arrestin 1
Therapeutics

Keywords

  • Asymmetric synthesis
  • BRET
  • G-protein
  • Multitarget
  • Pain
  • Radioligand competition binding
  • Tail flick test
  • β-arrestin

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

(2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2) : Discovery of a biased mu/delta opioid receptor agonist. / Pasquinucci, Lorella; Turnaturi, Rita; Calò, Girolamo; Pappalardo, Francesco; Ferrari, Federica; Russo, Giulia; Arena, Emanuela; Montenegro, Lucia; Chiechio, Santina; Prezzavento, Orazio; Parenti, Carmela.

In: European Journal of Medicinal Chemistry, Vol. 168, 15.04.2019, p. 189-198.

Research output: Contribution to journalArticle

Pasquinucci, L, Turnaturi, R, Calò, G, Pappalardo, F, Ferrari, F, Russo, G, Arena, E, Montenegro, L, Chiechio, S, Prezzavento, O & Parenti, C 2019, '(2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist', European Journal of Medicinal Chemistry, vol. 168, pp. 189-198. https://doi.org/10.1016/j.ejmech.2019.02.043
Pasquinucci, Lorella ; Turnaturi, Rita ; Calò, Girolamo ; Pappalardo, Francesco ; Ferrari, Federica ; Russo, Giulia ; Arena, Emanuela ; Montenegro, Lucia ; Chiechio, Santina ; Prezzavento, Orazio ; Parenti, Carmela. / (2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2) : Discovery of a biased mu/delta opioid receptor agonist. In: European Journal of Medicinal Chemistry. 2019 ; Vol. 168. pp. 189-198.
@article{e3af8312c43342ae8ee771654af8dc6b,
title = "(2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist",
abstract = "The pivotal role of the stereocenter at the N-substituent of the 6,7-benzomorphan scaffold was investigated combining synthetic and pharmacological approaches. 2R- and 2S-diastereoisomers of the multitarget MOR/DOR antinociceptive ligand LP2 (1) were synthesized and their pharmacological profile was evaluated in in vitro and vivo assays. From our results, 2S-LP2 (5) showed an improved pharmacological profile in comparison to LP2 (1) and 2R-LP2 (4). 2S-LP2 (5) elicited an antinociceptive effect with a 1.5- and 3-times higher potency than LP2 (1) and R-antipode (4), respectively. In vivo effect of 2S-LP2 (5) was consistent with the improved MOR/DOR efficacy profile assessed by radioligand binding assay, to evaluate the opioid receptor affinity, and BRET assay, to evaluate the capability to promote receptor/G-protein and receptor/β-arrestin 2 interaction. 2S-LP2 (5) was able to activate, with different efficacy, G-protein pathway over β-arrestin 2, behaving as biased agonist at MOR and mainly at DOR. Considering the therapeutic potential of both multitarget MOR/DOR agonism and functional selectivity over G-protein, the 2S-LP2 (5) biased multitarget MOR/DOR agonist could provide a safer treatment opportunity.",
keywords = "Asymmetric synthesis, BRET, G-protein, Multitarget, Pain, Radioligand competition binding, Tail flick test, β-arrestin",
author = "Lorella Pasquinucci and Rita Turnaturi and Girolamo Cal{\`o} and Francesco Pappalardo and Federica Ferrari and Giulia Russo and Emanuela Arena and Lucia Montenegro and Santina Chiechio and Orazio Prezzavento and Carmela Parenti",
year = "2019",
month = "4",
day = "15",
doi = "10.1016/j.ejmech.2019.02.043",
language = "English",
volume = "168",
pages = "189--198",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - (2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2)

T2 - Discovery of a biased mu/delta opioid receptor agonist

AU - Pasquinucci, Lorella

AU - Turnaturi, Rita

AU - Calò, Girolamo

AU - Pappalardo, Francesco

AU - Ferrari, Federica

AU - Russo, Giulia

AU - Arena, Emanuela

AU - Montenegro, Lucia

AU - Chiechio, Santina

AU - Prezzavento, Orazio

AU - Parenti, Carmela

PY - 2019/4/15

Y1 - 2019/4/15

N2 - The pivotal role of the stereocenter at the N-substituent of the 6,7-benzomorphan scaffold was investigated combining synthetic and pharmacological approaches. 2R- and 2S-diastereoisomers of the multitarget MOR/DOR antinociceptive ligand LP2 (1) were synthesized and their pharmacological profile was evaluated in in vitro and vivo assays. From our results, 2S-LP2 (5) showed an improved pharmacological profile in comparison to LP2 (1) and 2R-LP2 (4). 2S-LP2 (5) elicited an antinociceptive effect with a 1.5- and 3-times higher potency than LP2 (1) and R-antipode (4), respectively. In vivo effect of 2S-LP2 (5) was consistent with the improved MOR/DOR efficacy profile assessed by radioligand binding assay, to evaluate the opioid receptor affinity, and BRET assay, to evaluate the capability to promote receptor/G-protein and receptor/β-arrestin 2 interaction. 2S-LP2 (5) was able to activate, with different efficacy, G-protein pathway over β-arrestin 2, behaving as biased agonist at MOR and mainly at DOR. Considering the therapeutic potential of both multitarget MOR/DOR agonism and functional selectivity over G-protein, the 2S-LP2 (5) biased multitarget MOR/DOR agonist could provide a safer treatment opportunity.

AB - The pivotal role of the stereocenter at the N-substituent of the 6,7-benzomorphan scaffold was investigated combining synthetic and pharmacological approaches. 2R- and 2S-diastereoisomers of the multitarget MOR/DOR antinociceptive ligand LP2 (1) were synthesized and their pharmacological profile was evaluated in in vitro and vivo assays. From our results, 2S-LP2 (5) showed an improved pharmacological profile in comparison to LP2 (1) and 2R-LP2 (4). 2S-LP2 (5) elicited an antinociceptive effect with a 1.5- and 3-times higher potency than LP2 (1) and R-antipode (4), respectively. In vivo effect of 2S-LP2 (5) was consistent with the improved MOR/DOR efficacy profile assessed by radioligand binding assay, to evaluate the opioid receptor affinity, and BRET assay, to evaluate the capability to promote receptor/G-protein and receptor/β-arrestin 2 interaction. 2S-LP2 (5) was able to activate, with different efficacy, G-protein pathway over β-arrestin 2, behaving as biased agonist at MOR and mainly at DOR. Considering the therapeutic potential of both multitarget MOR/DOR agonism and functional selectivity over G-protein, the 2S-LP2 (5) biased multitarget MOR/DOR agonist could provide a safer treatment opportunity.

KW - Asymmetric synthesis

KW - BRET

KW - G-protein

KW - Multitarget

KW - Pain

KW - Radioligand competition binding

KW - Tail flick test

KW - β-arrestin

UR - http://www.scopus.com/inward/record.url?scp=85061983229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061983229&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2019.02.043

DO - 10.1016/j.ejmech.2019.02.043

M3 - Article

VL - 168

SP - 189

EP - 198

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -